News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ferrer Internacional and Medivir AB (MVIRb.F) Enter Agreement for Commercializing a New Treatment for Agitation Associated With Schizophrenia and Bipolar Disease in the Nordics


9/18/2013 10:10:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir AB (Nasdaq OMX: MVIR) (STO:MVIR-B) and Ferrer today announced that they have entered a license and distribution agreement for the commercialization of ADASUVE® (Staccato® Loxapine) in the Nordic region. In Europe, ADASUVE is approved for the treatment of mild to moderate agitation of patients with schizophrenia or bipolar disease. Under the terms of the agreement, Ferrer grants to Medivir the exclusive rights to promote, market, sell and distribute ADASUVE in the Nordic region – including Denmark, Finland, Norway, Iceland and Sweden. ADASUVE is a hand-held inhaler designed to deliver the drug to the deep lung, providing rapid systemic delivery in a simple, non-invasive manner. Medivir thus becomes the exclusive supplier of this new treatment therapy for the treatment of mild to moderate agitation of patients with schizophrenia or bipolar disease. In return, Ferrer will receive an up-front payment upon signature, and milestone payments conditional upon cumulative sales performance.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES